Johnson & Johnson (JNJ) Offering Possible 8.7% Return Over the Next 35 Calendar Days

Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $155.00 short call and a strike $165.00 long call offers a potential 8.7% return on risk over the next 35 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $155.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock rose above the $165.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

Panorama Capital Corp. announces LOI for qualifying transaction with U.S. based Avisa Pharma Inc.
Wed, 13 May 2020 17:05:00 +0000
KELOWNA, BC , May 13, 2020 /CNW/ – Panorama Capital Corp. (PANO-P.V) (the “Company” or “Panorama”), a capital pool company (“CPC”), is pleased to announce it has entered into a non-binding letter of intent dated May 12, 2020 (the “LOI”) to enter into an arm's length business combination transaction (the “Proposed Transaction”) with Avisa Pharma Inc. (“Avisa”). Established in 2010, Avisa is a private medical device company with its head office in Santa Fe, New Mexico and incorporated under the laws of the State of Delaware . Avisa has developed a quantitative, point-of-care diagnostic breath test known as the Avisa BreathTest (“ABT”) for rapidly detecting bacterial pneumonia and pulmonary infections in approximately 10 minutes.

Hedge Fund Tells Alexion Management to Sell Company
Tue, 12 May 2020 21:07:43 +0000
Elliott Advisors says most recent acquisition is an example of its questionable strategy Continue reading…

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
Tue, 12 May 2020 17:09:05 +0000
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Health-care ETFs rise as coronavirus treatments take center stage
Mon, 11 May 2020 17:12:00 +0000
Exchange-traded funds that track the health care sector pushed higher Monday as investors watched for progress on coronavirus treatments. The Select Sector SPDR ETF that tracks health care, often known by its ticker, XLV, was the best performer among all the S&P 500 sectors, up 1.4%, but several other health-care funds were beating it. The iShares U.S. Healthcare ETF rose 1.5%, the Fidelity MSCI Health Care Index was up 1.6%, and the Invesco S&P SmallCap Health Care ETF gained 1.9%. Despite coming from different companies and tracking different indexes, FHLC and PSCH have precisely the same holdings, in the same order, in their top ten, albeit with slightly differing weights. The five biggest holdings for both funds are: Johnson & Johnson , UnitedHealth Group Inc , Pfizer Inc , Merck & Co Inc. , and Abbott Laboratories .

Halozyme Therapeutics (HALO) Stock Is Absurdly Cheap Right Now
Mon, 11 May 2020 15:50:21 +0000
Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 […]

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.